Evidence map›Paper›PMID 20571543›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010

Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD).

Emilio Gonzalez-Gonzalez, Tycho J Speaker, Robyn P Hickerson, Ryan Spitler, Manuel A Flores, Devin Leake, Christopher H Contag, Roger L Kaspar

Open access · hybridAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Smart micro/nanoneedles for gene delivery.Iranian journal of basic medical sciences · 2026
    Review
  3. Article
  4. Review
  5. Transdermal delivery for gene therapy.Drug delivery and translational research · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Review
  13. Microneedles: an innovative platform for gene delivery.Drug delivery and translational research · 2015
    Review
  14. In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
  15. Article
  16. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.Journal of controlled release : official journal of the Controlled Release Society · 2013
    Article
  17. Article
  18. Microneedles for drug and vaccine delivery.Advanced drug delivery reviews · 2012
    Review
  19. Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Emilio Gonzalez-GonzalezDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Tycho J Speaker
Robyn P Hickerson
Ryan Spitler
Manuel A Flores
Devin Leake
Christopher H Contag
Roger L Kaspar
Stanford University · USThermo Fisher Scientific (United States) · US

Funding

Delivery of biologically active nucleic acids to epidermal cellsRC2AR058955 · NIAMS · TRANSDERM, INC. · PI CONTAG, CHRISTOPHER H, KASPAR, ROGER L · 2009 to 2010
$2.8M
Development of siRNA delivery methodologies using in vivo imaging modelsR44AR055881 · NIAMS · TRANSDERM, INC. · PI KASPAR, ROGER L · 2009 to 2009
$1.4M
NIAMS NIH HHS R44 AR055881NIAMS NIH HHS R44AR055881NIAMS NIH HHS RC2 AR058955NIAMS NIH HHS RC2AR058955
6 · The paper itself

Abstract

Despite rapid progress in the development of potent and selective small interfering RNA (siRNA) agents for skin disorders, translation to the clinic has been hampered by the lack of effective, patient-friendly delivery technologies. The stratum corneum poses a formidable barrier to efficient delivery of large and/or charged macromolecules including siRNAs. Intradermal siRNA injection results in effective knockdown of targeted gene expression but is painful and the effects are localized to the injection site. The use of microneedle arrays represents a less painful delivery method and may have utility for the delivery of nucleic acids, including siRNAs. For this purpose, we developed a loadable, dissolvable protrusion array device (PAD) that allows skin barrier penetration. The PAD tips dissolve upon insertion, forming a gel-like plug that releases functional cargo. PAD-mediated delivery of siRNA (modified for enhanced stability and cellular uptake) resulted in effective silencing of reporter gene expression in a transgenic reporter mouse model. PAD delivery of luciferase reporter plasmids resulted in expression in cells of the ear, back, and footpad skin as assayed by intravital bioluminescence imaging. These results support the use of PADs for delivery of functional nucleic acids to cells in the skin with an efficiency that may support clinical translation.

Indexed as

Drug CarriersAnimalsFemaleFootGene SilencingGenes, ReporterMiceMicroscopy, FluorescencePlasmidsRNA, Small InterferingSkinDrug CarriersRNA, Small Interfering

Identifiers

PMID20571543
PMCPMC2956931
OpenAlexW2061004440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.